Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$20.80 USD
-0.34 (-1.61%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.79 -0.01 (-0.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Arrowhead Pharmaceuticals, Inc. [ARWR]
Reports for Purchase
Showing records 21 - 40 ( 95 total )
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Announces 20 in 2025 Strategy; Multiple Programs Advancing to Phase 3 in 2023; Moderating Price Target to $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F3Q22 Earnings; Pipeline Is Firing on All Cylinders With Many Datasets on Track for 2H22 and 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Partnered Program Updates; Alpha One Program Continues to Shine; HBV Data Confirms Potential Need for Immunomodulator
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Outlines Next Generation Pulmonary Programs With Blockbuster Potential in Asthma, COPD, and IPF
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Potential Blockbuster Partnered Olpasiran Program Addressing Cardiovascular Disease Clears Phase 2 Hurdle; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F2Q22 Results; Pulmonary R&D Day Expected May 26; Alpha One Updates Expected Near-Term; CVD Programs on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
HCW "At Home" Recap: Reiterate Buy Ahead of Plethora of Data Updates on Broad RNAi Therapeutics Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
We cordially invite you to attend a hosted fireside chat with Arrowhead?s President and CEO, to discuss the recent progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Potential Blockbuster CVD, Complement, and Partnered Programs on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Leading RNAi TRiM Platform on Track to Generate Peak Annual Revenues of More Than $20B
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F3Q21 Results; Announces C3 Program; Enrollment in Key CVD Phase 2 Trials Underway; Upping PT to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Sell-off Tied to ARO-EnAC Phase 1/2 Study Halt Is Overdone; Valuable Liver-Directed Programs on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Generates Compelling Initial Data on Liver Fibrosis Target, With Positive Read-Through to ALNY program
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F2Q21 Results; On the Cusp of Validating RNAi Therapeutics Outside the Liver
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F1Q21 Results; Pipeline Advancing With Multiple Data Readouts on Track; Upping PT to $95; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Strong Finish to Transformational Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Alpha One Collaboration Clears Way to Focus on High Value Cardio-Metabolic and Pulmonary Franchises
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pipeline Is Firing on All Cylinders; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department